TFAP2B

Chr 6AD

transcription factor AP-2 beta

Also known as: AP-2B, AP-2beta, AP2-B, PDA2

This gene encodes a member of the AP-2 family of transcription factors. AP-2 proteins form homo- or hetero-dimers with other AP-2 family members and bind specific DNA sequences. They are thought to stimulate cell proliferation and suppress terminal differentiation of specific cell types during embryonic development. Specific AP-2 family members differ in their expression patterns and binding affinity for different promoters. This protein functions as both a transcriptional activator and repressor. Mutations in this gene result in autosomal dominant Char syndrome, suggesting that this gene functions in the differentiation of neural crest cell derivatives. [provided by RefSeq, Jul 2008]

Primary Disease Associations & Inheritance

Char syndromeMIM #169100
AD
Patent ductus arteriosus 2MIM #617035
AD
98
ClinVar variants
10
Pathogenic / LP
0.99
pLI score· haploinsufficient
1
Active trials
Clinical SummaryTFAP2B
🧬
Gene-Disease Validity (ClinGen)
TFAP2B-related congenital heart disease spectrum disorder · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 0.99). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
10 Pathogenic / Likely Pathogenic· 65 VUS of 98 total submissions
💊
Clinical Trials
1 active or recruiting trial — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.26LOEUF
pLI 0.990
Z-score 3.75
OE 0.05 (0.020.26)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
1.29Z-score
OE missense 0.77 (0.680.87)
191 obs / 248.1 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.05 (0.020.26)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.77 (0.680.87)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.10
01.21.6
LoF obs/exp: 1 / 18.3Missense obs/exp: 191 / 248.1Syn Z: -0.81

ClinVar Variant Classifications

98 submitted variants in ClinVar

Classification Summary

Pathogenic4
Likely Pathogenic6
VUS65
Likely Benign23
4
Pathogenic
6
Likely Pathogenic
65
VUS
23
Likely Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
1
0
3
0
4
Likely Pathogenic
0
2
4
0
6
VUS
2
59
3
1
65
Likely Benign
0
0
7
16
23
Benign
0
0
0
0
0
Total361171798

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

TFAP2B · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

TFAP2B-related Char syndrome

definitive
ADUndeterminedAltered Gene Product Structure
Dev. DisordersSkeletal
G2P ↗
missense variantinframe deletioninframe insertion

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

Char syndrome

MIM #169100

Molecular basis of disorder known

Autosomal dominant

Patent ductus arteriosus 2

MIM #617035

Molecular basis of disorder known

Autosomal dominant
📖
GeneReview available — TFAP2B
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
[Research progress of genetic research on Char syndrome].
Zhao M et al.·Zhonghua Yi Xue Yi Chuan Xue Za Zhi
2024Review
Top 10 resultsSearch PubMed ↗